A worldwide, Phase 2b trial evaluating etrasimod – an oral, selective, sphingosine 1 phosphate (S1P) receptor modulator – for the treatment of moderately to severely active Crohn’s disease.
Patients may be able to take part in the clinical program if they*:
- Are 18 to 80 years of age
- Have been diagnosed with Crohn’s disease for at least 3 months
- Have previously been on a Crohn’s disease treatment which did not work or which you could not tolerate
- Are currently experiencing an active flare (A flare usually consists of symptoms like frequent bowel movements or diarrhea, bloody stool, and/or abdominal pain. You may also experience fatigue, a lack of appetite, and weight loss.)
For more information please visit https://arenaibd.com/study-cultivate/
*Other eligibility criteria may apply